Lars Ny

4.8k total citations
114 papers, 3.0k citations indexed

About

Lars Ny is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Lars Ny has authored 114 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 46 papers in Oncology and 27 papers in Immunology. Recurrent topics in Lars Ny's work include Immunotherapy and Immune Responses (27 papers), Cancer Immunotherapy and Biomarkers (26 papers) and CAR-T cell therapy research (21 papers). Lars Ny is often cited by papers focused on Immunotherapy and Immune Responses (27 papers), Cancer Immunotherapy and Biomarkers (26 papers) and CAR-T cell therapy research (21 papers). Lars Ny collaborates with scholars based in Sweden, Australia and Denmark. Lars Ny's co-authors include Lars Grundemar, Jonas A. Nilsson, Karl‐Erik Andersson, Per Alm, Roger Olofsson Bagge, Erik Larsson, Henrik Jespersen, Nils Johan Fredriksson, Lisa M. Nilsson and Ulrika Stierner and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Lars Ny

104 papers receiving 2.9k citations

Peers

Countries citing papers authored by Lars Ny

Since Specialization

Citations

This map shows the geographic impact of Lars Ny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Ny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Ny more than expected).

Fields of papers citing papers by Lars Ny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Ny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Ny. The network helps show where Lars Ny may publish in the future.

Co-authorship network of co-authors of Lars Ny

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Ny. A scholar is included among the top collaborators of Lars Ny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Ny. Lars Ny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of liver metastases from uveal melanoma 2025 ·British journal of surgery ·Anne Huibers, Andrew Wong, Mark C. Burgmans, Lars Ny, Gustav Stålhammar, Ellen Kapiteijn, Jonathan S. Zager, Roger Olofsson Bagge	1
2	Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Charlotta All‐Eriksson, Christian Cahlin, Nils Elander, Hildur Helgadóttir, Jens Folke Kiilgaard, Sara Kinhult, Ingrid Ljuslinder, Jan Mattsson, Magnus Rizell, Malin Sternby Eilard, Gustav Ullenhag, Jonas A. Nilsson, Lars Ny, Per Lindnér, Roger Olofsson Bagge	0
3	1079MO Survival before and after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study 2024 ·Annals of Oncology ·Hafdís T. Helgadóttir, Lars Ny, Gustav Ullenhag, (unknown), (unknown), Roger Olofsson Bagge, Karolin Isaksson	3
4	Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study 2023 ·JNCI Journal of the National Cancer Institute ·Hildur Helgadóttir, Lars Ny, Gustav Ullenhag, (unknown), (unknown), Roger Olofsson Bagge, Karolin Isaksson	15
5	Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial). 2023 ·Journal of Clinical Oncology ·Roger Olofsson Bagge, (unknown), (unknown), Charlotta All‐Eriksson, Christian Cahlin, Nils Elander, Hildur Helgadóttir, Jens Folke Kiilgaard, Sara Kinhult, Ingrid Ljuslinder, Magnus Rizell, Malin Sternby Eilard, Gustav Ullenhag, Jonas A. Nilsson, Lars Ny, Per Lindnér	1
6	Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases 2023 ·eLife ·Joakim Karlsson, Vasu R. Sah, Roger Olofsson Bagge, Irina Kuznetsova, (unknown), Samuel Alsén, (unknown), Alka Saxena, Lars Ny, Lisa M. Nilsson, Jonas A. Nilsson	2
7	Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial) 2023 ·Journal of Clinical Oncology ·Roger Olofsson Bagge, (unknown), (unknown), Charlotta All‐Eriksson, Christian Cahlin, Nils Elander, Hildur Helgadóttir, Jens Folke Kiilgaard, Sara Kinhult, Ingrid Ljuslinder, Jan Mattsson, Magnus Rizell, Malin Sternby Eilard, Gustav Ullenhag, Jonas A. Nilsson, Lars Ny, Per Lindnér	33
8	622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·David J. Pinato, Ruth Plummer, Martin Gutierrez, Jeffrey Yachnin, (unknown), Martin Højgaard, Knut B. Smeland, William J. Edenfield, Hans Prenen, Lars Ny, Alan Anthoney, Nuria Kotecki, Stefan N. Symeonides, Louis Viviers, (unknown), (unknown), Udai Banerji	3
9	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma 2021 ·Melanoma Research ·Vasu R. Sah, Joakim Karlsson, Henrik Jespersen, Mattias F. Lindberg, Lisa M. Nilsson, Lars Ny, Jonas A. Nilsson	15
10	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis 2021 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Lars Ny, Christer Jensen, (unknown), Henrik Jespersen, Jan Borén, Malin Levin, Henrik Zetterberg, Anna Rudin, (unknown), (unknown)	17
11	Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection 2020 ·Case Reports in Oncology ·Magnus Rizell, Fredrik Åberg, (unknown), Lars Ny, (unknown), (unknown), Joar Svanvik, Per Lindnér	22
12	LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 2020 ·Annals of Oncology ·Ana Arance, Steven O’Day, Luis de la Cruz‐Merino, Teresa M. Petrella, (unknown), Lars Ny, Ana Carneiro, Alfonso Berrocal, Iván Márquez‐Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, A. David Smith, (unknown), Scott J. Diede, Clemens Krepler, Georgina V. Long	19
13	Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models 2020 ·Annals of Oncology ·Lars Ny, Larissa Yokota Rizzo, Valerio Belgrano, Joakim Karlsson, Henrik Jespersen, Louise Carstam, Roger Olofsson Bagge, Lisa M. Nilsson, Jonas A. Nilsson	30
14	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study 2019 ·BMC Cancer ·Henrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, Ana Carneiro, Hildur Helgadóttir, Ingrid Ljuslinder, Max Levin, Charlotta All‐Eriksson, Bengt Åndersson, Ulrika Stierner, Lisa M. Nilsson, Jonas A. Nilsson, Lars Ny	52
15	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma 2017 ·Cell Death and Disease ·Somsundar Veppil Muralidharan, Berglind O. Einarsdottir, Joydeep Bhadury, Mattias F. Lindberg, (unknown), Eric Campeau, Roger Olofsson Bagge, Ulrika Stierner, Lars Ny, Lisa M. Nilsson, Jonas A. Nilsson	15
16	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model 2017 ·Nature Communications ·Henrik Jespersen, Mattias F. Lindberg, Marco Donia, Elin Söderberg, Rikke Andersen, Ulrich Keller, Lars Ny, Inge Marie Svane, Lisa M. Nilsson, Jonas A. Nilsson	120
17	Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial 2014 ·Trials ·Roger Olofsson Bagge, Lars Ny, Malin Sternby Eilard, Magnus Rizell, Christian Cahlin, Ulrika Stierner, Ulf Lönn, Johan Hansson, Ingrid Ljuslinder, Lotta Lundgren, Gustav Ullenhag, Jens Folke Kiilgaard, Jonas A. Nilsson, Per Lindnér	29
18	Bacterial flora of the human oral cavity, and the upper and lower esophagus 2012 ·Diseases of the Esophagus ·(unknown), Gunnar Dahlén, M. Ruth, Lars Ny, Marianne Quiding‐Järbrink, Henrik Bergquist, (unknown)	89
19	Risk of clinically relevant bleeding in warfarin‐treated patients—influence of SSRI treatment 2009 ·Pharmacoepidemiology and Drug Safety ·Susanna M. Wallerstedt, (unknown), Anders Sundström, Lennart Stigendal, Lars Ny	49
20	Morphological relations between haem oxygenases, NO-synthase and VIP in the canine and feline gastrointestinal tracts 1997 ·Journal of the Autonomic Nervous System ·Lars Ny, (unknown), Bengt Larsson, Karl‐Erik Andersson	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact